MorphoSys (MOR) Competitors $18.96 0.00 (0.00%) As of 09/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MOR vs. QGEN, MRNA, BBIO, ELAN, VRNA, ROIV, GRFS, RVMD, RYTM, and LEGNShould you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Qiagen (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Grifols (GRFS), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. MorphoSys vs. Its Competitors Qiagen Moderna BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Grifols Revolution Medicines Rhythm Pharmaceuticals Legend Biotech MorphoSys (NASDAQ:MOR) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability. Do institutionals and insiders have more ownership in MOR or QGEN? 18.4% of MorphoSys shares are held by institutional investors. Comparatively, 70.0% of QIAGEN shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 9.0% of QIAGEN shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, MOR or QGEN? QIAGEN has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45QIAGEN$1.98B5.28$83.59M$1.6927.81 Which has more volatility and risk, MOR or QGEN? MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Do analysts rate MOR or QGEN? QIAGEN has a consensus price target of $49.69, indicating a potential upside of 5.72%. Given QIAGEN's stronger consensus rating and higher possible upside, analysts plainly believe QIAGEN is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00QIAGEN 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27 Is MOR or QGEN more profitable? QIAGEN has a net margin of 18.30% compared to MorphoSys' net margin of -226.79%. QIAGEN's return on equity of 14.77% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% QIAGEN 18.30%14.77%8.87% Does the media refer more to MOR or QGEN? In the previous week, QIAGEN had 21 more articles in the media than MorphoSys. MarketBeat recorded 21 mentions for QIAGEN and 0 mentions for MorphoSys. QIAGEN's average media sentiment score of 0.93 beat MorphoSys' score of 0.00 indicating that QIAGEN is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral QIAGEN Positive SummaryQIAGEN beats MorphoSys on 14 of the 16 factors compared between the two stocks. Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOR vs. The Competition Export to ExcelMetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$822.15M$5.76B$9.85BDividend YieldN/A4.84%6.71%4.51%P/E Ratio-5.451.0759.1122.53Price / Sales11.9926.59547.00119.09Price / CashN/A19.5637.0558.92Price / Book54.176.6410.916.06Net Income-$205.35M-$4.78M$3.29B$266.28M7 Day PerformanceN/A2.02%0.01%-0.76%1 Month PerformanceN/A20.76%7.06%3.83%1 Year PerformanceN/A30.62%50.09%24.39% MorphoSys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730QGENQiagen4.2785 of 5 stars$48.92-1.6%$49.69+1.6%+8.4%$11.06B$1.98B28.905,765Positive NewsMRNAModerna4.4241 of 5 stars$25.35-6.5%$42.88+69.2%-67.0%$10.55B$3.06B-3.375,800BBIOBridgeBio Pharma4.1821 of 5 stars$47.29-3.6%$61.35+29.7%+80.4%$9.38B$235.81M-11.56400News CoveragePositive NewsAnalyst ForecastELANElanco Animal Health3.1154 of 5 stars$17.80-0.6%$17.33-2.6%+14.4%$8.90B$4.48B20.709,000Analyst RevisionVRNAVerona Pharma PLC American Depositary Share2.5979 of 5 stars$105.62+0.1%$109.00+3.2%+290.2%$8.64B$221.67M-106.6930News CoveragePositive NewsROIVRoivant Sciences3.17 of 5 stars$11.64-2.3%$16.50+41.8%+7.0%$8.14B$29.05M-16.63860News CoveragePositive NewsAnalyst ForecastGRFSGrifols3.9365 of 5 stars$9.82-3.3%$10.30+4.9%+2.2%$6.99B$7.81B8.3923,822Positive NewsGap UpRVMDRevolution Medicines4.4891 of 5 stars$35.67-3.6%$69.92+96.0%-4.3%$6.92BN/A-7.93250Positive NewsInsider TradeRYTMRhythm Pharmaceuticals3.3217 of 5 stars$99.20-3.9%$101.57+2.4%+121.3%$6.86B$130.13M-32.96140News CoveragePositive NewsLEGNLegend Biotech3.532 of 5 stars$34.60-2.7%$73.00+111.0%-37.3%$6.53B$627.24M-39.322,609 Related Companies and Tools Related Companies QGEN Competitors MRNA Competitors BBIO Competitors ELAN Competitors VRNA Competitors ROIV Competitors GRFS Competitors RVMD Competitors RYTM Competitors LEGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOR) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
